Basket | Login | Register


Grifols presents clinical trial data on AMBAR study

Sunday 08 December 2019

On 6 December, the pharmaceutical company Grifols presented data from their latest trial in Alzheimer’s disease (AD) at the CTAD conference. The AMBAR (Alzheimer Management by Albumin Replacement) trial is based on a 14 month-plasma protein replacement therapy. It encompassed 496 participants with mild to moderate AD who were in between 55 and 85 years old. The study concluded over a year ago. Neuroimaging data that was conducted as part of the study and presented at the conference suggests that participants who received albumin and immunoglobulin showed less reduction in brain glucose metabolism as well as possibly less neuronal damage when compared to participants who received placebo. According to the press release, Grifols is going to meet with the Food and Drug Administration to discuss a clinical development program as well as the design of a further AMBAR II trial in order to deepen and complement the concluded study.